BINOSTOTM, the first and only effervescent osteoporosis medication approved by the FDA, delivers proven fracture prevention in an easy-to-swallow buffered solution.
FREIENBACH, Switzerland - Thursday, April 19th 2012 [ME NewsWire]
(BUSINESS WIRE)-- EffRx Pharmaceuticals SAannounced today that Mission
Pharmacal, San Antonio, Texas, has entered into a patent and technology
licensing agreement with EffRx Pharmaceuticals SA, Freienbach,
Switzerland, for the manufacturing and commercialization of BINOSTOTM
(alendronate sodium) Effervescent Tablets in the United States and
Canada. The U.S. Food and Drug Administration recently approved
BINOSTOTM to treat osteoporosis in postmenopausal women and to increase
bone mass in men with osteoporosis.
Utilizing EffRx’s formulation technology, BINOSTOTM is the first and
only buffered effervescent therapeutic to deliver the gold standard in
osteoporosis treatment and fracture prevention of alendronate sodium–in
an easy-to-swallow, buffered solution. A Harris Interactive Poll
concluded that up to 40 percent of American adults have difficulties
with swallowing tablets. That difficulty often results in patients
having to choose between enduring painful injections or forgoing
treatment for this chronic disease.
Dr. Robert Recker, President of the National Osteoporosis Foundation,
notes, “BINOSTO provides an important new innovation for patients
suffering with osteoporosis. BINOSTO offers those patients that struggle
with taking tablets the opportunity to obtain the proven fracture
prevention of alendronate in an easy-to-take, buffered solution.”
“We are very excited about our partnership with EffRx and look forward
to helping deliver BINOSTO to women with osteoporosis who have
difficulty with pills or shots and to men who also struggle with this
disease. Men’s bone health has previously been overlooked,” says Neil
Walsdorf Jr., President of Mission Pharmacal.
EffRx CEO, Christer Rosén adds, “We believe Mission is the logical
choice for bringing BINOSTO to the United States and Canadian markets.
Mission is focused on quality first and foremost and they have a long
history of educating patients and physicians in bone health. They also
have a well-established women’s health sales force where they have
proven that they can launch a product and drive it to a market
leadership position. We are extremely happy to have Mission as a
partner.”
Osteoporosis is a serious and often debilitating disease affecting more
than 200 million people worldwide. According to the National
Osteoporosis Foundation, the leading health organization dedicated to
the prevention of osteoporosis and broken bones, more than 10 million
people in the United States have osteoporosis and another 34 million are
estimated to have osteopenia, or low bone density, which is often the
precursor to osteoporosis.
Although it is commonly thought of as a “woman’s disease,” the problem
of osteoporosis in men has recently been recognized as an important
public health issue. It is true that women suffer relatively rapid bone
loss in the first few years after menopause. However, by about age 65
men and women lose bone mass at the same rate.
“With the commercialization rights to BINOSTO, we can further our
investment in promoting and treating bone health with a world-class
product that addresses both osteoporosis and pill-swallowing
difficulty,” notes Terry Herring, President of Mission Pharmacal
Consumer Operations. “We look forward to building strategic partnerships
that will ensure BINOSTO is widely promoted and available throughout
the United States and Canada.”
About BINOSTOTM
BINOSTOTM is a once weekly, strawberry flavored effervescent tablet
containing alendronate 70mg that rapidly dissolves in half a glass (4
oz.) of plain room temperature water to make a buffered solution.
BINOSTOTM is available in packs of four and 12 tablets.
BINOSTOTM was developed by EffRx based on an agreement with Merck &
Co, Inc. granting EffRx the worldwide rights to all effervescent and
related patents of FOSAMAX® (alendronate). Patents have been granted to
EffRx providing exclusivity for BINOSTOTM through February 2023.
Additional patents are pending.
About Mission Pharmacal
Mission Pharmacal is a privately held pharmaceutical company based in
San Antonio, Texas. For more than 65 years, the company has been
committed to meeting the unique healthcare needs of women throughout all
stages of life, pediatric patients, and those persons dealing with
urologic and dermatologic conditions. The company has a proven track
record of identifying unmet healthcare needs and developing both
innovative prescription and over-the-counter products to meet these
needs. Using only the purest ingredients, Mission Pharmacal provides
physicians and consumers with the highest quality pharmaceutical and
dietary supplement products on the market today. Mission Pharmacal is a
proud national supporter of the March of Dimes Foundation, whose mission
is to improve the health of babies by preventing birth defects,
premature birth, and infant mortality. For more information about the
company, visit www.missionpharmacal.com.
About EffRx
EffRx Pharmaceuticals SAis a drug delivery company based in Freienbach,
Switzerland. EffRx specializes in improving existing high volume
pharmaceutical products by utilizing its novel techniques in different
effervescent executions. The primary focus of EffRx is in metabolic bone
disease, oncology supportive care, pediatric medications, and support
to larger companies in Life Cycle Management. For more information about
the company, visit www.effrx.com.
Contacts
EffRx Contact:
Christer Rosén, Chairman & CEO
Tel: +41 799636600
Email: info@effrx.com
Mission Contact:
Drew Deeter
DEETER Strategic Public Relations
215.348.3890
drew@deeterusa.com
No comments:
Post a Comment